Gene Jockeys Kindle Ò Ebook

  • ebook
  • 260 pages
  • Gene Jockeys
  • Nicolas Rasmussen
  • 15 December 2016
  • 9781421413419

2 thoughts on “Gene Jockeys

  1. David Usharauli David Usharauli says:

    In Gene Jockeys Nicolas Rasmussen revisits evens that led to development of the first 5 major biotech drugs based on DNA recombination that created new biotech industry These 5 recombinant drugs were insulin human growth hormone interferons erythropoietin and tPA Several pioneering biotech companies such as Genentech Amgen Genetics Institute Biogen Cetus and events and people who led drug development are being discussed freuently in too much detailsIt was so revealing to know that all these 5 drugs were simultaneously pursued by several biotech companies as if they were eavesdropping on each other's work and did not have any original ideas themselvesposted by David

  2. Cheyenne Sloan Cheyenne Sloan says:

    Pretty good but very technical Not for the feint of heart

Leave a Reply

Your email address will not be published. Required fields are marked *

Gene Jockeys The biotech arena emerged in the 1970s and 1980s when molecular biology one of the fastest moving areas of basic science in the twentieth century met the business world Gene Jockeys is a detailed study of the biotech projects that led to five of the first ten recombinant DNA drugs to be approved for medical use in the United States human insulin human growth hormone alpha interferon erythropoietin and tissue plasminogen activatorDrawing on corporate documents obtained from patent litigation as well as interviews with the ambitious biologists who called themselves gene jockeys historian Nicolas Rasmussen chronicles the remarkable and often secretive work of the scientists who built a new domain between academia and the drug industry in the pursuit of intellectual rewards and big payouts In contrast to some who critiue the rise of biotechnology Rasmussen contends that biotech was not a swindle even if the public did pay a very high price for the development of what began as public scientific resources Within the biotech enterprise the work of corporate scientists went well beyond what biologists had already accomplished within universities and it accelerated the medical use of the new drugs by several yearsIn his technically detailed and readable narrative Rasmussen focuses on the visible and often heavy hands that construct and maintain the markets in public goods like science He looks closely at how science follows money and vice versa as researchers respond to the pressures and potential rewards of commercially viable innovations In biotechnology many of those engaged in crafting markets for genetically engineered drugs were biologists themselves who were in fact trying to do scienceThis book captures that heady fleeting moment when a biologist could expect to do great science through the private sector and be rewarded with both wealth and scientific acclaim